Hoth Therapeutics Approved To Proceed With First-In-Human Phase 2a Clinical Trial Of HT-001 For Treatment Of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics has received approval to proceed with a Phase 2a clinical trial of HT-001, aimed at treating skin toxicities associated with epidermal growth factor receptor inhibitors. Three new sites, GW University Hospital, UC Irvine, and Northwell Health, have joined the trial.
July 16, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hoth Therapeutics has been approved to proceed with a Phase 2a clinical trial for HT-001, targeting skin toxicities from epidermal growth factor receptor inhibitors. The addition of three new trial sites could accelerate the trial process.
The approval to proceed with the Phase 2a trial is a significant milestone for Hoth Therapeutics, potentially leading to positive clinical outcomes and future revenue streams. The addition of new trial sites suggests a robust trial process, which is likely to be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100